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Distinct Role of IL-27 in Immature
and LPS-Induced Mature Dendritic
Cell-Mediated Development of CD4+
CD127+3G11+ Regulatory T Cell
Subset
Fang Zhou*†, Guang-Xian Zhang and Abdolmohamad Rostami*
Department of Neurology, Thomas Jefferson University, Philadelphia, PA, United States
Interleukin-27 (IL-27) plays an important role in regulation of anti-inflammatory responses
and autoimmunity; however, themolecular mechanisms of IL-27 inmodulation of immune
tolerance and autoimmunity have not been fully elucidated. Dendritic cells (DCs) play a
central role in regulating immune responses mediated by innate and adaptive immune
systems, but regulatory mechanisms of DCs in CD4+ T cell-mediated immune responses
have not yet been elucidated. Here we show that IL-27 treated mature DCs induced
by LPS inhibit immune tolerance mediated by LPS-stimulated DCs. IL-27 treatment
facilitates development of the CD4+ CD127+3G11+ regulatory T cell subset in vitro
and in vivo. By contrast, IL-27 treated immature DCs fail to modulate development of
the CD4+CD127+3G11+ regulatory T cell sub-population in vitro and in vivo. Our results
suggest that IL-27 may break immune tolerance induced by LPS-stimulated mature DCs
through modulating development of a specific CD4+ regulatory T cell subset mediated
by 3G11 and CD127. Our data reveal a new cellular regulatory mechanism of IL-27
that targets DC-mediated immune responses in autoimmune diseases such as multiple
sclerosis (MS) and experimental autoimmune encephalomyelitis (EAE).
Keywords: dendritic cell, immune tolerance, immunotherapy, regulatory T cell, IL-27
INTRODUCTION
Interleukin-27 (IL-27) is an important cytokine that plays a critical role in regulation of immune
responses in vivo (1). Previous research has shown that IL-27 is an anti-inflammatory cytokine. For
example, it blocks Th17-mediated immune responses (2). However, recent data also indicate that
IL-27 plays the role of an inflammatory cytokine that facilitates T cell-mediated immune responses
(3–5). These contradictory results suggest the complex regulatory mechanisms of IL-27 in vivo(1).
CD127 is a subunit of interleukin-7 (IL-7) receptor. It is composed of 459 amino acids and is
expressed in mature T cells, monocytes and macrophages. In particular, CD127 is a biomarker of
regulatory T cells (Tregs) (6, 7). Several sub-populations of Tregs have been defined according to the
importance of CD127 expression on CD4+ T cells (8).
3G11 is a membrane antigen expressed on murine CD4+ T cells. 3G11 is a ganglioside with
mobility between GD1a and GD1b complexes in the human brain. 3G11 antigen is identified as
the disialoganglioside IV3(NeuAc)2-GgOse4Cer. The immune function of 3G11 on CD4+ T cells
has not been fully elucidated. Recent research demonstrated that 3G11 may be a biomarker of Treg
subsets (8–13).
Zhou et al. DC-Mediated Development of Tregs
Dendritic cells (DCs) are important immune regulatory cells
that play a central role in development of T cells such as CD4+
T helper cells. DCs modulate development and differentiation of
T cells through production of multiple cytokines such as IL-27
(5). It is not clear whether IL-27 can affect DC-mediated CD4+
T cell immune responses. The effect of IL-27 on development of
CD4+ regulatory T cells was examined in this project. Our data
show that IL-27 modulates development of mature DC-mediated
differentiation of Treg subsets.
Regulatory T cells are important immune cells in vivo
and they play a central role in induction of immune
tolerance and anti-inflammatory responses (14, 15). Multiple
subsets of Tregs have been reported. For example, our
previous data show that there are two subpopulations of
Tregs including CD4
+CD25+FoxP3+GITR+CD127+3G11+ and
CD4+CD25+FoxP3+GITR+CD127+3G11− Treg subsets in vivo.
Although the immune function of these two new subsets of
Tregs is unclear, the number of Treg sub-populations mediated
by 3G11 and CD127 is different in mice with experimental
autoimmune encephalomyelitis (EAE) development and those
with immune tolerance. However, the regulatory mechanisms
of CD4+CD127+3G11+ Tregs are still unclear (8). Our project
is focused on whether or not IL-27 plays an important role
in the development of CD4+CD127+3G11+ Tregs mediated by
immature or mature DCs induced by LPS. Our results will show
that IL-27 modulates development of CD4+CD127+3G11+ Tregs
mediated by mature DCs, and they may help to reveal a new
mechanism of IL-27 in mature DC-mediated immune responses.
MATERIALS AND METHODS
Mice
Wild type C57 BL/6J female mice (8–12 weeks) were purchased
from The Jackson Laboratory (Bar Harbor, ME, USA). All mice
were bred in Thomas Jefferson Animal Care facilities and all
experimental procedures were approved by the Institutional
Animal Care andUse Committee of Thomas JeffersonUniversity.
Immunogen and Peptide
Mouse MOG35−55 peptide (MEVGWYRSPFSRVVHLYRNGK),
an ingredient of myelin oligodendrocyte glycoprotein (MOG),
was obtained from Invitrogen (Invitrogen, Carlsbad, CA, USA).
Isolation of Bone Marrow
As described previously, femurs and tibiae were isolated from
muscle tissue of mice. The intact bones were then sterilized
with 70% ethanol for 5min and washed with phosphate-buffered
saline (PBS). Bone ends were cut and the bone marrow was
Abbreviations: APC, Allophycocyanin; CD, Cluster of differentiation; CFA,
Complete Freund’s adjuvant; DC, Dendritic cell; EAE, Experimental autoimmune
encephalomyelitis; FCS, Fetal Calf Serum; Fig, Figure; GM –CSF, Granulocyte-
macrophage colony-stimulating factor; IL, Interleukin; i. p., Intraperitoneal; i.v.,
Intravenous; KLH, Keyhole limpet hemocyanin; LPS, Lipopolysaccharide; MOG,
Myelin oligodendrocyte glycoprotein; 2-ME, 2-mercaptoethanol; MS, Multiple
sclerosis; PBS, Phosphate-buffered saline; pDCs, Plasmacytoid dendritic cells; PI,
Propidium Iodide; PT, Pertussis toxin; s.c., Subcutaneous; SD, Standard deviation;
SEM, Standard error of arithmetic mean; Th, T helper cells.
flushed with PBS. Cellular clusters within the bone marrow
suspension were disintegrated and washed with PBS (8, 16–20).
Bone Marrow-Derived DC Culture
As described previously, leucocytes from bone marrow were
fed in bacteriological 100mm Petri dishes (Falcon, Becton
Dickinson, Heidelberg, Germany) at 2 × 106 cells per dish.
Cells were cultured in RPMI1640 complete medium (Gibco-BRL,
Eggenstein, Germany) including penicillin (100 U/ml, Sigma, St.
Louis, MO, USA), streptomycin (100 U/ml, Sigma), L-glutamine
(2mM, Sigma), 2-mercaptoethanol (2-ME, 50µM, Sigma), 10%
heated, inactivated and filtered (0.22µm,Milipore, Inc., Bedford,
MA, USA) Fetal Calf Serum (FCS, Sigma) and granulocyte-
macrophage colony-stimulating factor (GM-CSF, PeproTech,
Rocky Hill, NJ, USA) at 20 ng/ml at day 0 (10ml medium per
dish) (8, 16–20).
At day 3, 10ml fresh medium with GM-CSF (20 ng/ml) was
added to each dish and, at day 6, half of the medium (about
10ml supernatant) was collected and centrifuged at 300 g for
5min. Subsequently, cells were re-suspended in 10ml fresh
medium with GM-CSF (20 ng/ml) and were then re-fed in the
original dish. Only non-adherent cells (DCs) were harvested and
seeded in a fresh dish; 10ml fresh medium including GM-CSF
(20 ng/ml) was added at day 8 (8, 16–20).
Cells were also treated with lipopolysaccharide (LPS, Sigma)
for 24 h at 1µg/ml. LPS was isolated from K. Pneumoniae. DCs
or LPS-treated DCs were pulsed with 0.1µM MOG peptide
for 30min and then washed twice with PBS at 300 g × 5min
before i.v. transfer to EAE mice. DCs were treated with IL-
27 at 100 ng/ml for 72 h before conducting flow cytometry
assay or i.v transfer experiments. Fresh non-adherent DCs were
then collected and washed with PBS at 300 g for 5min and
characterized by flow cytometry or i.v. transferred to EAE mice.
More than 90% of cells expressed DC marker CD11c (8, 16–20).
Flow Cytometry
MOG-primed T lymphocytes were isolated from EAE mice and
incubated with anti-mouse CD4 (Pacific blue), CD25 (APC),
CD127 (PerCP-Cy5.5), 3G11 (PE-Cy7) and GITR (APC-Cy7)
antibodies (Biolegend). Cells were washed twice with 5% FCS in
PBS at 300 g for 5min, fixed with 5% formalin in PBS at 4◦C for
2 h and then permeated for intracellular staining (8, 16–20).
For intracellular staining, spleen cells were stimulated by
leukocyte activator (BD) for 6 h. Splenocytes were then washed
twice with 5% FCS in PBS at 300 g for 5min and fixed with
5% formalin (Sigma) in PBS at 4◦C for 2 h. After cells were
washed with permeabilization buffer (Biolegend) twice at 300 g
× 10min, anti-mouse FoxP3 (PE) antibody (Biolegend) was
incubated with cells at 4◦C for 24 h. Cells were then washed with
permeabilization buffer twice at 300 g for 5min, re-suspended in
0.5ml cell staining buffer (Biolegend), and tested in a FACSAria
(BD Biosciences, San Jose, CA, USA). Data were analyzed using
FlowJo software (Treestar, Ashland, OR, USA) (8, 16–20).
Generation of Effector T Cells in vitro
C57 BL/6J mice were immunized with MOG35−55 peptide
(Invitrogen) 200 µg, QuilA (Sigma) 20 µg, and keyhole limpet
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hemocyanin (KLH, Sigma) 20 µg per mouse at day 0. Spleen
cells were then isolated at day 10 after immunization. CD4+
T lymphocytes were purified with mouse CD4+ T cell subset
column kit (R&D Systems). CD4+ T cells (1× 106 cells/per well)
were co-cultured with DCs at 10:1 (T cells: DCs) and pulsed
with MOG 35−55 peptide at 0.1µM in complete medium with
mouse IL-2 at 1 ng/ml for 3 days. Cells were harvested andMOG-
primed CD4+ T cells were gated and analyzed by flow cytometry
(8, 16–20).
EAE Induction and Treatment
C57BL/6J mice (female, 8–12 week) were immunized with
MOG35−55 peptide/complete Freund’s adjuvant (CFA, Sigma) at
200µg/200µl/per mouse (subcutaneous injection, s.c.). Pertussis
toxin (PT, Sigma) was simultaneously injected at 200 ng/per
mouse (intraperitoneal injection) and the second PT injection
was conducted after 48 h. EAE was assessed following standard
clinical scores: 0.5: paralysis of half the tail, 1: paralysis of whole
tail, 2: paralysis of tail and one leg, 3: paralysis of tail and two legs,
4: moribund, 5: death (8, 16–20).
Mice were divided into five groups. DCs were washed with
PBS twice and were immediately injected via tail vein (3 ×
105 cells/per mouse/per time) on days 11, 14, and 17 post-
immunization (p.i): (1) injected with PBS only (EAE control);
(2) injected with DCs pulsed with MOG peptide; (3) injected
with IL-27-treated DCs pulsed with MOG peptide; (4) injected
with LPS-DCs pulsed with MOG peptide; (5) injected with
LPS and IL-27-treated DCs pulsed with MOG peptide (8, 16–
20).
At day 25 p.i., splenocytes were isolated and stimulated with
MOG peptide (0.1µM) and mouse IL-2 (1 ng/ml) for 3 days.
Cells were then harvested for flow cytometry assay (8, 16–20).
Statistical Analysis
Experimental data were analyzed using Prism software
(GraphPad, La Jolla, CA, USA). A two-way ANOVA test
was performed for analysis of clinical score of EAE; t tests
were conducted for analysis of flow cytometry data. Error bars
represent the mean and standard deviation (SD) or standard
error of arithmetic mean (SEM). Results are considered to
show a significant difference if the P value is less than 0.05
(8, 16–20).
RESULTS
IL-27-Treated Immature DCs do not Affect
Expression of Treg-Associated Molecules
on CD4+ T Cells
Since CD25, CD127, FoxP3, GITR, and 3G11 are Treg-associated
molecules and expressed on CD4+ T cells, we supposed that IL-
27-treated DCs may affect expression of CD25, CD127, FoxP3,
GITR, and 3G11 on CD4+ T cells and then regulate development
of Tregs via modulating expression of Treg-associated molecules.
To test whether IL-27-treated immature bone marrow-derived
DCs can affect protein expression of Treg-associated molecules
on MOG-primed CD4+ T cells, DCs (Thin line) or IL-27-treated
DCs (Thick line) were pulsed withMOG peptide and co-cultured
FIGURE 1 | Expression of Treg-associated molecules on MOG-primed CD4
+
T cells co-culture with immature DCs (Thin line) or IL-27-treated immature DCs
(Thick line) pulsed with MOG peptide in vitro. C57 BL/6J mice were immunized
with MOG (200 µg)/Quil A (20 µg) / KLH (20 µg)/per mouse at day 0.
Splenocytes were harvested at day 10. CD4+ T cells were then isolated using
mouse CD4+ T cell subset column kit (R and D Systems). CD4+ T
Lymphocytes were re-stimulated with MOG peptide (0.1µM) and IL-2 (1 ng/ml)
for 72 h. Cells were then stained by anti-mouse CD25 (A), CD127 (B), FoxP3
(C), GITR (D), and 3G11 (E) antibodies. Protein expression of Treg-associated
molecules on CD4+ T cells is shown. Error bars indicated in this figure
represent mean and SD of triplicate determinations of mean fluorescence
intensity (MFI) of Treg-associated molecule expression on CD4
+ T cells (n = 3,
t test, PA = 0.4198; PB = 0.4450; PC = 0.6047; PD = 0.8372; PE = 0.2523;
NS, no significant difference).
with MOG-primed CD4+ T cells. The expression of CD25,
CD127, FoxP3, GITR, and 3G11 on CD4+ T cells co-cultured
with MOG-loaded DC or MOG-pulsed DC (MOG-DCs) treated
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with IL-27 is shown (Figures 1A–E). The experimental data
indicate that there is no significant difference in expression of
Treg-associatedmolecules on CD4
+ T cells incubated withMOG-
DCs or MOG-DCs-treated with IL-27.
Nor do IL-27-Treated Mature DCs Induced
by LPS Affect Expression of
Treg-Associated Molecules on
MOG-Primed CD4+ T Cells
Although IL-27-treated immature DCs do not affect protein
expression of Treg-associated molecules on CD4
+ T cells
(Figure 1), it is unclear whether or not mature DCs induced
by LPS can do that. To detect whether or not IL-27 treatment
canmodulate mature DC-mediated expression of Treg-associated
molecules on CD4+ T cells, MOG-pulsed mature bone marrow-
derived DCs induced by LPS were treated with IL-27 (Thick
line) or without IL-27 treatment (Dot line) and co-cultured with
MOG-primed CD4+ T cells. The expression of CD25, CD127,
FoxP3, GITR, and 3G11 on CD4+ T cells is demonstrated
(Figures 2A–E). Our data indicate that expression of Treg-
associated molecules on CD4+ T cells co-cultured with IL-27-
treatedmature DCs is similar to that on CD4+ T cells co-cultured
with mature DCs without IL-27 treatment. It can be concluded
that IL-27 treatment does not modulate either immature or
mature DC-mediated expression of CD25, CD127, FoxP3, GITR,
and 3G11 on MOG-primed CD4+ T cells.
IL-27 Treatment Facilitates Development of
CD4+CD127+3G11+ Tregs Mediated by
LPS-Induced Mature DCs
Although immature and mature DCs treated with IL-27
do not affect expression of Treg-associated molecules on
CD4+ T cells (Figures 1, 2), we assumed that IL-27-treated
immature or mature DCs may still modulate development
of Treg sub-populations. To test whether IL-27 can affect
immature and mature DC-mediated development of CD4+
Treg subsets, immature, and mature DCs were incubated with
or without IL-27 treatment. Immature and mature DCs were
then pulsed with MOG peptide and co-cultured with MOG-
primed CD4+ T cells. Phenotypes of CD4+ Tregs-mediated
by CD127 and 3G11 are shown (Figure 3). The experimental
results indicate that immature DCs treated with IL-27 cannot
modulate development of CD4+CD127+3G11+ Treg subset;
however, LPS-induced mature DCs treated with IL-27 can
enhance development of the CD4+CD127+3G11+ Treg sub-
population (Figure 3). This suggests that LPS may modulate
mature DC-mediated development of CD4+ Treg subsets in
vitro.
IL-27-Treated Mature DCs Block Immune
Tolerance Induced by LPS-Stimulated DCs
in vivo
We have investigated the effect of immature and mature DCs
treated with IL-27 on development of Tregs in vitro (Figures 1–
3). It is necessary for establishment of in vivo model to detect
whether or not immature and mature DCs treated with IL-27
FIGURE 2 | Protein expression of Treg-associated molecules on MOG-primed
CD4+ T cells incubated with LPS-induced mature DCs or IL-27-treated
mature DCs pulsed with MOG peptide in vitro. Bone marrow-derived dendritic
cells were stimulated with LPS (1µg/ml) for 24 hrs. LPS-stimulated DCs were
also simultaneously incubated with IL-27 (20 ng/ml) (Thick line) for 72 hrs or
had no IL-27 treatment (Dot line). DCs were then co-cultured with
MOG-primed CD4+ T cells as shown in Figure 1. Protein expression of CD25
(A), CD127 (B), FoxP3 (C), GITR (D), and 3G11 (E) on CD4+ T cells is shown.
Error bars indicated in this figure represent mean and SD of MFI of
Treg-associated molecules expressing on CD4
+ T cells in three independent
experiments (n = 3, t test, PA = 0.8809; PB = 0.3012; PC = 0.2879; PD =
0.7744; PE = 0.7549; NS, no significant difference).
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FIGURE 3 | IL-27 treatment facilitates LPS-induced mature DCs-mediated development of CD4+CD127+3G11+ Treg subset in vitro. Bone marrow-derived DCs
shown in Figures 1, 2 were treated with IL-27 (20 ng/ml, 72 h) or/and LPS (1µg/ml, 24 h) or without LPS or IL-27 incubation. DCs were then co-cultured with
MOG-primed CD4+ T cells indicated in Figures 1, 2 for 72 h. CD4+CD25+FoxP3+GITR+ cells were gated. The frequency of CD127+3G11+ Tregs is shown.
Isotype control is CD4+ T cells incubated with isotype control antibodies. Error bars shown in this figure represent mean and SD of frequency of
CD4+CD127+3G11+ Tregs in three independent experiments (n = 3, t test, P (DC,DC+IL−27) = 0.1357; P(DC+LPS,DC+LPS+IL−27) = 0.0002).
can regulate development of Tregs. To test whether or not IL-27
treated immature and mature DCs can affect MOG-primed
CD4+ T cell-induced autoimmunity in vivo, immature and
LPS-induced mature DCs were pulsed with MOG peptide and
incubated with or without IL-27 treatment. Immature and
mature DCs were then i.v transferred into C57BL/6J mice
immunized with MOG peptide to induce EAE. Our data indicate
that IL-27 treatment blocks immune tolerance mediated by LPS-
inducedmature DCs. By contrast, IL-27 treatment does not affect
the development of EAE in mice that are i. v. transferred with
immature DCs (Figure 4). The experimental results suggest that
IL-27 may affect mature DC-mediated immune responses but
that it does not affect immature DC-mediated immune responses.
IL-27 Treated Immature DCs do Not Affect
Expression of Treg-Associated Molecules
on CD4+ T Cells ex vivo
Our data of in vitro assay have shown that IL-27-treated
immature DCs do not affect expression of Treg-associated
molecules on CD4+ T cells (Figure 1), however, it is still
unknown whether or not IL-27-treated immature DCs can affect
expression of Treg-associated molecules on CD4
+ T cells in
vivo. To test whether or not IL-27-treated immature DCs can
modulate expression of Treg-associated molecules on CD4
+ T
cells in vivo, MOG peptide-pulsed immature DCs incubated
with IL-27 or without IL-27 treatment were i.v. transferred
into EAE mice shown in Figure 4 at day 11, 14, and 17 after
immunization. Lymphocytes were isolated from mice which are
i.v transferred with IL-27-treated DCs or immature DCs without
IL-27 treatment shown in Figure 4 at day 25. Expression of Treg-
associated molecules on CD4+ T cells was detected using flow
cytometry. Our results demonstrated that there is no difference
in expression of Treg -associated molecules, including CD25,
CD127, FoxP3, GITR, and 3G11, on CD4+ T cells isolated from
mice that are i.v. transferred with IL-27-treated immature DCs or
DCs without IL-27 incubation (Figures 5A–E). Our data suggest
that IL-27-treated immature DCs do not affect development of
Tregs in vivo.
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FIGURE 4 | i.v. transfer of IL-27-treated mature DCs induced by LPS inhibits
immune tolerance mediated by LPS-stimulated DCs in vivo. C57 BL/6J mice
were immunized with MOG peptide (200 µg/per mouse) and CFA. Immature
dendritic cells (DCs) were incubated with IL-27 (DCs+IL-27) or LPS
(DCs+LPS) or both IL-27 and LPS (DCs+LPS+IL-27). Mice in control group
were i.v. transferred with PBS. EAE was then induced and shown by clinical
score. Error bars in this figure represent mean and SEM of triplicate
determinations of EAE clinical score in one experiment (n = 3, two-way
ANOVA test, P (DC,DC+IL−27) = 0.7960; P(DC+LPS,DC+LPS+IL−27) = 0.0001;
NS, no significant difference).
IL-27-Treated Mature DCs do Not Affect
Expression of Treg-Associated Molecules
on CD4+ T Cells ex vivo
We have testified that IL-27-treated mature DCs do not affect
expression of Treg-associated molecules on CD4
+ T cells in vitro
(Figure 2), however, it is still unclear that whether or not IL-27-
treated mature DCs can modulate expression of Treg-associated
FIGURE 5 | IL-27-treated immature DCs do not affect expression of
Treg-associated molecules on CD4
+ T cells ex vivo. Spleen cells were isolated
from mice treated with PBS (Shade) or DCs (Dot line) or DCs+IL-27 (Thin line)
indicated in Figure 4. T lymphocytes were re-stimulated by MOG peptide
(0.1µM) and IL-2 (1ng/ml) for 72 h. The expression of CD25 (A), CD127 (B),
FoxP3 (C), GITR (D), and 3G11 (E) on CD4+ T cells is shown. Error bars
demonstrated in this figure represent mean and SD of MFI of Treg-associated
molecules present on CD4+ T cells in three independent experiments (n = 3, t
test, PA = 0.1944; PB = 0.1476; PC = 0.2879; PD = 0.7744; PE = 0.7549;
NS, no significant difference).
molecules on CD4+ T cells in vivo. To determine whether IL-27-
treated mature DCs can modulate expression of Treg-associated
molecules on CD4+ T cells in vivo, IL-27-treated mature DCs
induced by LPS or mature DCs without IL-27 treatment were
i.v. transferred into EAE mice shown in Figure 4 at day 11, 14
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FIGURE 6 | IL-27-treated mature DCs induced by LPS do not affect
expression of Treg-associated molecules on CD4
+ T cells ex vivo.
LPS-stimulated DCs (Thin line) or IL-27-treated mature DCs induced by LPS
(Thick line) were i.v. transferred into mice shown in Figure 4. Spleen cells were
isolated and re-stimulated with MOG peptide (0.1µM) and IL-2 (1 ng/ml) for 72
hrs. The expression of CD25 (A), CD127 (B), FoxP3 (C), GITR (D), and 3G11
(E) on CD4+ T cells is shown. Error bars indicated in this figure represent
mean and SD of MFI of Treg-associated molecules expressing on CD4
+ T cells
in three independent experiments (n = 3, t test, PA = 0.7015; PB = 0.8555;
PC = 0.4659; PD = 0.7642; PE = 0.9505; NS, no significant difference).
and 17 after immunization. Protein expression of CD25, CD127,
FoxP3, GITR, and 3G11 on CD4+ T cells was tested using flow
cytometry. The experimental data show that i.v. transfer of IL-
27-treated mature DCs or mature DCs without IL-27 treatment
failed to modulate expression of Treg-associated molecules on
CD4+ T cells (Figures 6A–E). Our results suggest that IL-27-
treated mature DCs do not affect development of Tregs through
regulating expression of Treg-associated molecules on CD4
+ T
cells in vivo.
IL-27-Treated Mature DCs Facilitate
Development of CD4+ CD127+3G11+ Treg
Subset ex vivo
Our results of in vitro assay demonstrated that IL-27-treated
mature DCs elicit development of CD4+ CD127+3G11+ Treg
subset (Figure 3), however, it is unknown whether or not
IL-27-treated mature DCs also can facilitate development of
CD4+ CD127+3G11+ Treg subset in vivo. To detect whether
or not IL-27-treated mature or immature DCs can regulate
development of Treg sub-populations in vivo, LPS-induced
mature DCs and immature DCs without LPS stimulation
were pulsed with MOG peptide and incubated with or
without IL-27 treatment. IL-27-treated immature/mature DCs
or immature/mature DCs without incubation with IL-27 were
i.v. transferred into EAE mice shown in Figure 4 at day 11,
14 and 17 after immunization. Lymphocytes were isolated
from mice that had been i.v. transferred with IL-27-treated
immature/mature DCs or immature/mature DCs without IL-
27 treatment shown in Figure 4 at day 25. Our results indicate
that immature DCs incubated with or without IL-27 treatment
did not modulate development of CD4+3G11+CD127+ Treg
subset but that mature DCs treated with IL-27 facilitated
development of CD4+ CD127+3G11+ Treg sub-populations ex
vivo (Figure 7). Our data suggest that IL-27-treated mature DCs
may block autoimmunity (Figure 4) through upregulation of
CD4+CD127+3G11+ Tregs development in vivo.
DISCUSSION
IL-27 is a novel cytokine whose immune function has not
yet been fully elucidated. Chiyo et al. reported that tumor
cells expressing IL-27 activate CD4+ T helper cells, CD8+
cytotoxic T lymphocytes and natural killer cells (21, 22). IL-
27 shows an effect of anti-tumor immunity as a possible
therapeutic target for cancer (21). IL-27 plays an important
role in T cell differentiation and regulation of T cell-mediated
immune responses. For example, IL-27 produced by dendritic
cells facilitates the polarization of T helper 1 cells in Lewis
rats (23). Harker et al. recently found that IL-27-mediated
signaling is necessary for anti-viral immunity (24). Moreover,
IL-27 promotes differentiation of T helper 17 cells in vivo (25).
Our data also indicate that IL-27 inhibits LPS-induced mature
DC-mediated immune tolerance. These data suggest that IL-27
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FIGURE 7 | IL-27 facilitates LPS-stimulated mature DC-mediated development of CD4+CD127+3G11+ Treg subset ex vivo. Bone marrow-derived DCs were pulsed
with MOG peptide and treated with IL-27 (20 ng/ml, 72 h) (DCs+IL-27) or LPS (DCs+LPS) (1µg/ml, 24 h) or both LPS and IL-27 (DCs+LPS+IL-27). These DCs were
then i.v. transferred into mice with EAE shown in Figure 4. Mice treated with PBS are control. Spleen cells were isolated and re-stimulated with MOG peptide (0.1µM)
and IL-2 (1 ng/ml) for 72 h. Cells were collected and CD4+CD25+FoxP3+GITR+ Tregs were gated. The frequency of CD127
+3G11+ cells is demonstrated. T
lymphocytes incubated with isotype control antibodies are isotype control. Error bars indicated in this figure represent mean and SD of frequency of
CD4+CD127+3G11+ cells in three independent experiments [n = 3, t test, P(DC,DC+IL−27) = 0.8682; P(DC+LPS,DC+LPS+IL−27) = 0.0105].
is a pro-inflammatory cytokine and a positive regulator in T
cell-mediated immune responses.
Interestingly, the experimental data also indicate that IL-27
is an anti-inflammatory cytokine and inhibits development of
autoimmunity in vivo. For instance, Mascanfroni et al. reported
that IL-27 induces expression of CD39 on DCs and blocks
development of T helper 1 and 17 cells to inhibit EAE induction
(26). Tsoumarkidou et al. also found that tolerogenic CD1c+
DCs regulate development of Tregs via IL-27/IL-10 inducible
co-stimulatory ligands (27). Rostami et al. have published data
showing that the induction of peripheral tolerance is dependent
on IL-27-mediated signal transduction pathway in DCs (28).
These data suggest that regulatory mechanisms of IL-27 in the
immune system are extremely complex and that IL-27 may play
a dual role in equilibrium between autoimmunity and immune
tolerance. Our results demonstrate that IL-27 does not affect
immature DC-mediated immune responses but that it facilitates
mature DC-mediated CD4+CD127+3G11+ Treg development.
This suggests that the immune function of IL-27 on DCs is
dependent on their maturation.
The cellular and molecular regulatory mechanisms of IL-27
have been recently investigated. For example, it is known that IL-
27 canmodulate development and biological function of T helper
17 cells, dendritic cells, NK cells and neutrophils (22, 25, 29, 30).
IL-27 produced by DCs is necessary for trafficking of Tregs
to locate in tumor (31), and pulmonary CD1c+ DC-mediated
development of Tregs is dependent on IL-27/IL-10/inducible
costimulator ligand (27). IL-27 also facilitates development of
Treg and induces immune tolerance in vivo (32). By contrast, our
data indicate that IL-27-treated mature DCs elicit development
of CD4+CD127+3G11+ Treg subset and inhibits mature DC-
mediated immune tolerance in vivo (Figure 7).
The immunological significance of this study is that we
find a new subset of CD4+ Tregs mediated by 3G11 and
CD127. Biological function of CD4+CD127+3G11+ Tregs may be
different from that of conventional CD4+ Tregs. Previous studies
showed that CD4+ Tregs is a negative regulator of autoimmunity.
By contrast, the frequency of CD4+CD127+3G11+ Tregs
increases in mice in which LPS-stimulated DC-mediated
immune tolerance is inhibited. This new sub-population of Tregs
Frontiers in Immunology | www.frontiersin.org 8 November 2018 | Volume 9 | Article 2562
Zhou et al. DC-Mediated Development of Tregs
may be a positive regulator which facilitates T cell-mediated
immune responses in vivo. This has never been reported.
IL-27 can act as both pro-and anti-inflammatory cytokine,
however, molecular mechanisms of IL-27 to modulate
autoimmunity and immune tolerance have not yet been
fully elucidated. Our data indicated that IL-27 does not affect
immature DC-mediated immune responses, however, IL-27 can
block immune tolerance induced by LPS-stimulatedmature DCs.
IL-27 acts as a pro-inflammatory cytokine to inhibit immune
function of LPS-treated mature DCs. Interestingly, IL-27 only
elicits development of CD4+CD127+3G11+ Tregs mediated
by mature DCs induced by LPS. IL-27 does not affect that of
Treg subset mediated by immature DCs. It may be dependent
on maturation of DCs whether IL-27 plays a role of pro- or
anti-inflammatory cytokine in vivo.
The interesting question is how IL-27 regulates LPS-
stimulated mature DC-mediated immune tolerance in vivo.
There is little amount of data to reveal it. The molecular
mechanisms of IL-27 to block immune tolerance mediated by
LPS-treated mature DCs should be investigated in the future
so that a new immune therapy using CD4+CD127+3G11+
Treg sub-population can be designed to treat human
diseases.
In summary, Our results imply that CD4+CD127+3G11+
cells may be a type of positive Tregs which are different from
conventional CD4+ Tregs which inhibit autoimmunity in
vivo. This new subset of Tregs are CD127 positive cells and
conventional CD4+ Tregs express CD127 with low level,
although both of them are CD4+CD25+FoxP3+GITR+
cells. Biological function of CD4+CD127+3G11+
Tregs may be different from that of conventional
CD4+CD25+CD127lowFoxP3+GITR+ Tregs. Immune functions
of this new CD4+CD127+3G11+ Treg subset should be
investigated in future studies.
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